Verastem Oncology (VSTM) 2011年年度报告「NASDAQ」.pdf

1、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-K(Mark One)xxANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF1934 For the fiscal year ended December 31,2011 or ooTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURI

2、TIES EXCHANGEACT OF 1934 For the transition period from to Commission file number 001-35403 Verastem,Inc.(Exact name of registrant as specified in its charter)Delaware27-3269467(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)215 First Street,Suite 440Ca

3、mbridge,Massachusetts02142(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code:(617)252-9300 Securities registered pursuant to Section 12(b)of the Act:Title of each className of each exchange on whichregisteredCommon Stock,$0.0001 par valueNASDAQ Global

4、Market Securities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.o Yes x No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Se

5、ction 15(d)of the Act.o Yes x No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and

6、(2)has been subject to such filingrequirements for the past 90 days.o Yes x No Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein,and will not be contained,to thebest of registrants knowledge,in definitive proxy or information sta